End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 EGP | -0.33% | +1.36% | -5.10% |
May. 19 | Ibnsina Pharma Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 03 | Ibnsina Pharma Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company shows low valuation levels, with an enterprise value at 0.18 times its sales.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.10% | 62.53M | - | ||
-54.62% | 10.13B | B- | ||
-44.50% | 8.54B | B | ||
-19.34% | 6.49B | B | ||
-3.00% | 6.29B | C+ | ||
+92.00% | 5.25B | C | ||
-2.48% | 4.61B | D- | ||
+6.16% | 4.55B | B | ||
-31.43% | 3.72B | C | ||
+6.00% | 3.1B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ISPH Stock
- Ratings Ibnsina Pharma